D. E. Shaw & Co., Inc. Rhythm Pharmaceuticals, Inc. Put Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Put Options
1 transactions
Others Institutions Holding RYTM
# of Institutions
193Shares Held
67.1MCall Options Held
834KPut Options Held
78.6K-
Black Rock Inc. New York, NY6.74MShares$399 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA6.57MShares$389 Million0.29% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$379 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$360 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$230 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.3B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...